Anti-Angiogenic Agents in Management of Sarcoma Patients: Overview of Published Trials

We reviewed all fully published clinical trials assessing anti-angiogenic agents in sarcoma patients (last issue, January 13, 2020). Anti-angiogenic macromolecules (e.g., bevacizumab or ombrabulin) provide disappointing results. Many multikinase inhibitors have been assessed with non-randomized phas...

Descripción completa

Detalles Bibliográficos
Autores principales: Cren, Pierre-Yves, Lebellec, Loïc, Ryckewaert, Thomas, Penel, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732617/
https://www.ncbi.nlm.nih.gov/pubmed/33330082
http://dx.doi.org/10.3389/fonc.2020.594445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732617/
https://www.ncbi.nlm.nih.gov/pubmed/33330082
http://dx.doi.org/10.3389/fonc.2020.594445

Ejemplares similares